Similar Papers

Paper Title
Journal
Date
Author
Immune-Related Adverse Events and Outcomes in Patients with Advanced Non–Small Cell Lung Cancer: A Predictive Marker of Efficacy?
Jordi Remon ... Benjamin Besse
Journal of Thoracic Oncology | VOL. 14
Jordi Remon, et. al.Jordi Remon ... Benjamin Besse
23 Apr 2019
The Challenges of Third-Generation EGFR Tyrosine Kinase Inhibitors in the Therapy of Advanced NSCLC
Fen Wang ... Qing Zhou
Journal of Thoracic Oncology | VOL. 17
Fen Wang, et. al.Fen Wang ... Qing Zhou
17 Mar 2022
New Horizons in Chemotherapy: Platforms for Combinations in First-Line Advanced Non-small Cell Lung Cancer
Rogerio C Lilenbaum
Journal of Thoracic Oncology | VOL. 3
Rogerio C LilenbaumRogerio C Lilenbaum
01 Jun 2008
136P - TTF1 Expression in Advanced Non-Small Cell Lung Cancer: Impact on Survival Outcome
S Elsamany ... E Bukhari
Annals of Oncology | VOL. 26
S Elsamany, et. al.S Elsamany ... E Bukhari
01 Apr 2015
View more papers

More From: Journal for ImmunoTherapy of Cancer

Paper Title
Journal
Date
Author
Real-world outcomes with tisagenlecleucel in aggressive B-cell lymphoma: subgroup analyses from the CIBMTR registry
Daniel J Landsburg ... Cameron J Turtle
Journal for ImmunoTherapy of Cancer | VOL. 13
Daniel J Landsburg, et. al.Daniel J Landsburg ... Cameron J Turtle
09 Feb 2025
Phase I study of efineptakin alfa (NT-I7) for the treatment of Kaposi sarcoma
Ramya Ramaswami ... Chia-Ching Jackie Wang
Journal for ImmunoTherapy of Cancer | VOL. 13
Ramya Ramaswami, et. al.Ramya Ramaswami ... Chia-Ching Jackie Wang
06 Feb 2025
Complete metabolic response as early predictor of long-term efficacy after adoptive T cell therapy using tumor-infiltrating lymphocytes
Troels Holz Borch ... Inge Marie Svane
Journal for ImmunoTherapy of Cancer | VOL. 13
Troels Holz Borch, et. al.Troels Holz Borch ... Inge Marie Svane
06 Feb 2025
Pembrolizumab hybrid dosing is non-inferior to flat dosing in advanced non-small cell lung cancer: a real-world, retrospective bicenter cohort study
Michiel M Smeenk ... Willemijn S M E Theelen
Journal for ImmunoTherapy of Cancer | VOL. 13
Michiel M Smeenk, et. al.Michiel M Smeenk ... Willemijn S M E Theelen
06 Feb 2025
View more papers

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.